Department of Information Science, University at Albany-State University of New York, Albany, NY, USA.
Soc Sci Med. 2021 Jun;278:113942. doi: 10.1016/j.socscimed.2021.113942. Epub 2021 Apr 16.
The pharmaceutical industry spends billions of dollars every year for marketing its products to US health care providers. This study investigates the association between industry marketing payments and physicians' prescription in New York and Massachusetts, and examines the effect of the Massachusetts payment restriction policy on this association in comparison with the New York State that has no payment restriction policy. Three panel data models (fixed effects regression (FE), first difference regression (FD), and first difference with lagged independent variable (LFD)) were used to establish the association accounting for unobserved confounders and reverse causality. The main indicator is the total amount of industry payments for meals, drug samples, consulting fees, etc. (excluding research funding, and ownership). Dependent variables are a) yearly days' supply of Medicare Part D prescriptions, b) yearly costs of prescribed prescriptions. Secular time trends, as well as differences between the two states were controlled in all models. All three panel models showed significant positive association between industry payments and physician prescriptions. Particularly, these models show that in the base year (2014), a 1% increase in the annual industry payments was associated with (0.01%-0.04%) increase in days' supply of medication, and (0.01%-0.05%) increase in prescription costs for NYS providers. Moreover, FE and FD models show that compared to NYS physicians, the association of industry payments with days' supply and costs of Medicare Part D prescriptions was (0.01%-0.02%) smaller for MA physicians. Because of the smaller sample size and lower power, the LFD model did not detect a significant difference between the NYS and MA providers. The findings of this study provide additional evidence that industry payments are associated with increases in the volume and cost of Medicare prescriptions. Moreover, these findings provide preliminary evidence that payment restriction policies negatively moderate this association, which calls for further research.
制药业每年花费数十亿美元向美国医疗保健提供者推销其产品。本研究调查了纽约和马萨诸塞州的行业营销支付与医生处方之间的关联,并比较了有支付限制政策的马萨诸塞州与没有支付限制政策的纽约州,考察了马萨诸塞州的支付限制政策对这种关联的影响。使用了三个面板数据模型(固定效应回归(FE)、一阶差分回归(FD)和带有滞后自变量的一阶差分(LFD))来建立关联,以解释未观察到的混杂因素和反向因果关系。主要指标是行业支付的餐费、药品样本、咨询费等总额(不包括研究资金和所有权)。因变量是 a)医疗保险处方药的每年供应天数,b)规定处方的每年费用。在所有模型中都控制了世俗时间趋势以及两个州之间的差异。所有三个面板模型都显示出行业支付与医生处方之间存在显著的正相关关系。特别是,这些模型表明,在基年(2014 年),行业支付的年增长率增加 1%,与纽约州医生的药物供应天数增加 0.01%-0.04%和处方费用增加 0.01%-0.05%相关。此外,FE 和 FD 模型表明,与纽约州医生相比,马萨诸塞州医生的行业支付与医疗保险处方药的供应天数和成本的关联较小,为 0.01%-0.02%。由于样本量较小且统计效能较低,LFD 模型未检测到纽约州和马萨诸塞州医生之间存在显著差异。本研究的结果提供了额外的证据,表明行业支付与医疗保险处方数量和成本的增加有关。此外,这些发现初步表明,支付限制政策对这种关联具有负向调节作用,这需要进一步研究。